Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686455 | 0.90 | KDM4C (0.60) | KDM4CPTGDR2ATAD2NR4A2HRH4 | |
| SCHEMBL17686450 | 0.80 | KDM4C (0.61) | KDM4CPTGDR2ATAD2NR4A2HRH4 | |
| SCHEMBL17686461 | 0.75 | KDM4C (0.62) | KDM4CPTGDR2ATAD2NR4A2HRH4 | |
| SCHEMBL17610169 | 0.75 | KDM4C (1.00) | KDM4C | |
| SCHEMBL19580369 | 0.74 | KDM4C (0.49) | KDM4CHRH4KDM4ESMN1; SMN2 | |
| SCHEMBL22102705 | 0.70 | NR4A2 (0.42) | ATAD2NR4A2TRPV1DAONPC1 | |
| SCHEMBL17686470 | 0.68 | KDM4C (0.61) | KDM4CPTGDR2ATAD2HRH4DAO | |
| SCHEMBL17686466 | 0.68 | KDM4C (0.61) | KDM4CPTGDR2ATAD2HRH4DAO | |
| SCHEMBL16433109 | 0.67 | KDM4C (0.45) | KDM4C | |
| SCHEMBL17610206 | 0.66 | KDM4C (1.00) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGDR2 3279/4885ATAD2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.